These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23615769)

  • 1. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Ferreiro JL; Homs S; Berdejo J; Roura G; Gómez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Marcano AL; Gómez-Hospital JA; Angiolillo DJ; Cequier Á
    Thromb Haemost; 2013 Jul; 110(1):110-7. PubMed ID: 23615769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    Jin HY; Yang TH; Kim DI; Chung SR; Seo JS; Jang JS; Kim DK; Kim DK; Kim KH; Seol SH; Nam CW; Hur SH; Kim W; Park JS; Kim YJ; Kim DS
    Int J Cardiol; 2013 Sep; 167(5):1877-81. PubMed ID: 22682702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
    Nührenberg TG; Trenk D; Leggewie S; Ristau I; Amann M; Stratz C; Hochholzer W; Valina CM; Neumann FJ
    Platelets; 2013; 24(7):549-53. PubMed ID: 23216528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kuliczkowski W; Greif M; Gąsior M; Kaczmarski J; Pres D; Poloński L
    Kardiol Pol; 2011; 69(6):531-7. PubMed ID: 21678284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.
    Patti G; Bárczi G; Orlic D; Mangiacapra F; Colonna G; Pasceri V; Barbato E; Merkely B; Edes I; Ostojic M; Wijns W; Di Sciascio G
    J Am Coll Cardiol; 2011 Oct; 58(15):1592-9. PubMed ID: 21958886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
    Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
    Larson DM; Duval S; Sharkey SS; Solie C; Tschautscher C; Lips DL; Burke MN; Steinhubl S; Henry TD
    Am Heart J; 2010 Jul; 160(1):202-7. PubMed ID: 20598993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).
    Mikkelsson J; Paana T; Lepantalo A; Karjalainen PP
    Int J Cardiol; 2016 Jan; 202():463-6. PubMed ID: 26436674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
    Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
    Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
    Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
    Bonello L; Berbis J; Laine M; Armero S; Bessereau J; Jacquin L; Bonello C; Camillieri E; Barragan P; Dignat-George F; Paganelli F; Camoin-Jau L
    Thromb Haemost; 2012 Jul; 108(1):101-6. PubMed ID: 22535315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Li Y; Tai BC; Sia W; Phua QH; Richards MA; Low A; Chan KH; Teo SG; Sim TB; Lee CH; Roe MT; Yeo TC; Tan HC; Chan MY
    J Thromb Thrombolysis; 2012 Nov; 34(4):499-505. PubMed ID: 22855283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction.
    Zalewski J; Durak M; Lech P; Gajos G; Undas A; Nessler J; Rosławiecka A; Zmudka K
    Kardiol Pol; 2012; 70(7):677-84. PubMed ID: 22825940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Perl L; Sasson L; Weissler-Snir A; Greenberg G; Vaknin-Assa H; Kornowski R; Assali A; Lev EI
    Coron Artery Dis; 2015 Dec; 26(8):665-70. PubMed ID: 26378953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry).
    Bailleul C; Puymirat E; Aissaoui N; Schiele F; Ducrocq G; Coste P; Blanchard D; Brasselet C; Elbaz M; Steg PG; Le Breton H; Bonnefoy-Cudraz E; Montalescot G; Cottin Y; Goldstein P; Ferrières J; Simon T; Danchin N;
    Am J Cardiol; 2016 Jan; 117(1):17-21. PubMed ID: 26541905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.